| Literature DB >> 28655487 |
Moheb M Nasr1, Markus Krumme2, Yoshihiro Matsuda3, Bernhardt L Trout4, Clive Badman5, Salvatore Mascia6, Charles L Cooney4, Keith D Jensen4, Alastair Florence7, Craig Johnston7, Konstantin Konstantinov8, Sau L Lee9.
Abstract
Continuous manufacturing plays a key role in enabling the modernization of pharmaceutical manufacturing. The fate of this emerging technology will rely, in large part, on the regulatory implementation of this novel technology. This paper, which is based on the 2nd International Symposium on the Continuous Manufacturing of Pharmaceuticals, describes not only the advances that have taken place since the first International Symposium on Continuous Manufacturing of Pharmaceuticals in 2014, but the regulatory landscape that exists today. Key regulatory concepts including quality risk management, batch definition, control strategy, process monitoring and control, real-time release testing, data processing and management, and process validation/verification are outlined. Support from regulatory agencies, particularly in the form of the harmonization of regulatory expectations, will be crucial to the successful implementation of continuous manufacturing. Collaborative efforts, among academia, industry, and regulatory agencies, are the optimal solution for ensuring a solid future for this promising manufacturing technology.Keywords: ICH; ISCMP; PAT; continuous manufacturing; control strategy; process monitoring; process validation; real-time release; regulatory considerations; traceability
Mesh:
Year: 2017 PMID: 28655487 DOI: 10.1016/j.xphs.2017.06.015
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534